EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Histiocytic Sarcoma: A Review and Update

Yuki Shinohara, Shizuhide Nakayama iD, Mikiko Aoki iD, Jun Nishio iD

International Journal of Molecular Sciences · 03.09.2025 · 26 (17) · 8554

DOI: 10.3390/ijms26178554 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.09.2025. Verfasst von Yuki Shinohara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan. Hauptthemen laut MEDLINE: Histiocytic Sarcoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histiocytic sarcoma (HS) is an ultra-rare hematopoietic neoplasm that frequently occurs in extranodal sites of adults. Clinically, HS demonstrates aggressive behavior and can arise de novo or in association with other hematological neoplasms. The median overall survival from the time of diagnosis is approximately six months. Histologically, HS is composed of sheets of large, round to oval cells with abundant eosinophilic cytoplasm and can be confused with a variety of benign and malignant conditions. Immunohistochemistry plays a crucial role in the diagnosis of HS, showing expression of CD163, CD68, lysozyme, and PU.1 and negative staining with follicular dendritic cell markers and myeloid cell markers. Recent studies have demonstrated a high rate of PD-L1 expression, suggesting a potential therapeutic target. Several genomic alterations have been identified in HS, including mutations involving the RAS/MAPK and PI3K/AKT/mTOR signaling pathways, CDKN2A mutations/deletions, and TP53 mutations. There is no standard protocol for the management of HS. Surgical resection with or without radiotherapy is the most common first-line treatment for unifocal/localized disease. The systemic treatment options for multifocal/disseminated disease are very limited. This review provides an overview of the current knowledge on the clinicoradiological features, histopathology, pathogenesis, and management of HS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytic SarcomaHumansBiomarkers, TumorSignal TransductionMutation

Stichwörter der Autor:innen

diagnosishematopoietic neoplasmhistiocytic sarcomamalignant histiocytosispathogenesistreatment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Section of Orthopaedic Surgery, Department of Medicine, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan.
  • Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
  • Department of Pathology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.

ORCID-Profile: Shizuhide Nakayama, Mikiko Aoki, Jun Nishio

Zitieren

APA

Shinohara, Y., Nakayama, S., Aoki, M., & Nishio, J. (2025). Histiocytic Sarcoma: A Review and Update. International Journal of Molecular Sciences, 26(17), 8554. https://doi.org/10.3390/ijms26178554

Vancouver

Shinohara Y, Nakayama S, Aoki M, Nishio J. Histiocytic Sarcoma: A Review and Update. International Journal of Molecular Sciences. 2025;26(17):8554. doi:10.3390/ijms26178554

BibTeX
@article{Shinohara2025,
  author = {Shinohara, Yuki and Nakayama, Shizuhide and Aoki, Mikiko and Nishio, Jun},
  title = {Histiocytic Sarcoma: A Review and Update},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8554},
  doi = {10.3390/ijms26178554}
}
Kostenlos starten →